Literature DB >> 21155882

Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease.

Jayani Manchanayake1, Shivakumar Chitturi, Christopher Nolan, Geoffrey C Farrell.   

Abstract

BACKGROUND AND AIMS: Despite strong associations between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D), it is unclear which patients need oral glucose tolerance testing (OGTT). Relationships between hyperglycemia, postprandial hyperinsulinemia and NAFLD severity also need clarification.
METHODS: Among 111 consecutive NAFLD patients, 35 had established T2D; 70 of the remaining 76 underwent 75G OGTT with fasting, 60 and 120 min insulin. Hepatic fibrotic severity was estimated by NAFLD fibrosis score and evidence of cirrhosis.
RESULTS: Twenty-four (33%) showed abnormal glucose tolerance: seven T2D, 17 impaired glucose tolerance (IGT). NAFLD patients with newly diagnosed T2D or IGT were (mean) 9 years older and more likely female (54% vs 30%). Fasting hyperglycemia (5.6-6.9 mmol/L) had limited sensitivity (46%) but high specificity (89%) for identifying patients with IGT/T2D; positive and negative predictive values were 69% and 76%. Postprandial hyperinsulinemia (120 min) was evident in all non-diabetic NAFLD cases, and values were higher (151 ± 87 vs 82 ± 53 mU/L, P = 0.001) in those with abnormal OGTT. Patients with established diabetes were more likely to have cirrhosis (40%) than those with IGT (12%) or normal glucose tolerance (4%).
CONCLUSIONS: All NAFLD patients have postprandial hyperinsulinemia, and OGTT reveals a high frequency of previously unsuspected IGT or T2D. Such testing would identify individuals who may benefit from early intervention to improve insulin sensitivity and prevent diabetes and progression to cirrhosis.
© 2011 Journal of Gastroenterology and Hepatology Foundation and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21155882     DOI: 10.1111/j.1440-1746.2010.06528.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  20 in total

1.  The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.

Authors:  Reona Morio; Hideyuki Hyogo; Masahiro Hatooka; Kei Morio; Hiromi Kan; Tomoki Kobayashi; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Hidenori Ochi; Yoneda Masayasu; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2016-06-28       Impact factor: 7.527

Review 2.  Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment.

Authors:  Nathalie C Leite; Cristiane A Villela-Nogueira; Claudia R L Cardoso; Gil F Salles
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

Review 3.  Predictive roles of intraoperative blood glucose for post-transplant outcomes in liver transplantation.

Authors:  Chul Soo Park
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

4.  Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease.

Authors:  Jennifer E Lambert; Maria A Ramos-Roman; Jeffrey D Browning; Elizabeth J Parks
Journal:  Gastroenterology       Date:  2013-12-04       Impact factor: 22.682

5.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

6.  Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice.

Authors:  Fahrettin Haczeyni; Laurence Poekes; Hans Wang; Auvro R Mridha; Vanessa Barn; W Geoffrey Haigh; George N Ioannou; Matthew M Yeh; Isabelle A Leclercq; Narcissus C Teoh; Geoffrey C Farrell
Journal:  Obesity (Silver Spring)       Date:  2016-11-02       Impact factor: 5.002

Review 7.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 8.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

9.  Non-Alcoholic Fatty Liver Disease in Early Pregnancy Predicts Dysglycemia in Mid-Pregnancy: Prospective Study.

Authors:  Leanne R De Souza; Howard Berger; Ravi Retnakaran; Paraskevi A Vlachou; Jonathon L Maguire; Avery B Nathens; Philip W Connelly; Joel G Ray
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

Review 10.  Sphingolipids in obesity, type 2 diabetes, and metabolic disease.

Authors:  S B Russo; J S Ross; L A Cowart
Journal:  Handb Exp Pharmacol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.